Form 4 for ENGN enGene Therapeutics Inc.
Accepted 2026-09-24 16:40:34 ET · period of report 2026-09-22 · accession 0001552781-26-000501 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-24 16:40 | 2026-09-22 | ENGN | Grossman William | Interim Chief Medical Off, Dir | P - Purchase | $1.97 | +5,102 | 5,102 | New | +$10.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-09-22 | P | A | 5,102 | $1.97 | 5,102 | D | — | — |